Clinical Trial Update: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study is evaluating the combination of alisertib and osimertinib in patients with metastatic EGFR-mutant non-small cell lung cancer; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alisertib (alisertib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Collin Blakely | Conditions: Lung Cancer Metastatic, EGFR Gene Mutation | Phase 1 | Status: RECRUITING